Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]

This article refers to:

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study

Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D. Int J Chron Obstruct Pulmon Dis. 2016;11:2543–2551.

On page 2547, Figure 5x-axis, the dose mentioned in the label for IND should have read “150 µg od” instead of “110 µg od” and the dose for GLY should have read “50 µg od” instead of “110 µg od”.